UDP 003
Alternative Names: UDP-003Latest Information Update: 10 Nov 2023
At a glance
- Originator Underdog Pharmaceuticals
- Developer Cyclarity Therapeutics
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Atherosclerosis; Carotid stenosis; Coronary artery disease; Niemann-Pick disease type C; Peripheral arterial disorders
- Research Unspecified
Most Recent Events
- 21 Sep 2023 Early research in Unspecified in USA (PO) (Cyclarity Therapeutics pipeline, September 2023)
- 21 Sep 2023 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Cyclarity Therapeutics pipeline, September 2023)
- 21 Sep 2023 Preclinical trials in Carotid stenosis in USA (unspecified route) (Cyclarity Therapeutics pipeline, September 2023)